Holen Sie sich die Stockscreener-App
6.63
3.77%
-0.26
Handel nachbörslich:
6.63
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
NTLA DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action – NTLA - TradingView
Intellia stock plunges to 52-week low of $6.49 amid market challenges - Investing.com
Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN - Yahoo Finance
NTLA Investors Have Opportunity to Lead Intellia Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - PR Newswire
Intellia Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Expands Team: Strategic RSU Grants Worth 8,400 Shares to Attract Top Talent - Stock Titan
Intellia begins phase 3 trial for gene-editing therapy - Investing.com
Intellia Therapeutics Announces First Patient Dosed in the - GlobeNewswire
Revolutionary One-Shot Gene Therapy Enters Final Testing Phase for Fatal Nerve Disease - Stock Titan
Intellia Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 14, 2025 to Discuss Your RightsNTLA - PR Newswire
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - GlobeNewswire
NTLA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
NTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Long Term Trading Analysis for (NTLA) - news.stocktradersdaily.com
ROSEN, A TOP-RANKED FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
ROSEN, A TOP-RANKED FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA - TradingView
Intellia Therapeutics (NASDAQ:NTLA) Trading Down 9.6%Should You Sell? - MarketBeat
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA - GlobeNewswire Inc.
Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy? - Yahoo Finance
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: - GlobeNewswire
Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) should contact Levi & Korsinsky about pending Class ActionNTLA - PR Newswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - StreetInsider
8 Best Gene-Editing Stocks to Buy - Insider Monkey
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
2025-03-31 | Intellia Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationNTLA | NDAQ:NTLA | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming DeadlinesNTLA - PR Newswire
Intellia Focuses on Pipeline Development Amid Stiff Competition - Yahoo Finance
Contact The Gross Law Firm by April 14, 2025 Deadline to Join Class Action Against Intellia Therapeutics, Inc.(NTLA) - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure - Bluefield Daily Telegraph
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication (NTLA) - Seeking Alpha
Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNTLA - Marketscreener.com
Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion. - TradingView
Shareholders that Lost Money on Intellia Therapeutics, Inc. (NTLA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class ... - Bluefield Daily Telegraph
Levi & Korsinsky Notifies Shareholders of Intellia - GlobeNewswire
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication - Yahoo Finance
The Gross Law Firm Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025NTLA - PR Newswire
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for InvestorsContact Levi & Korsinsky - The National Law Review
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure - Bluefield Daily Telegraph
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA - TradingView
Intellia Therapeutics, Inc. Shareholders are Reminded of - GlobeNewswire
Intellia Therapeutics, Inc. Shareholders are Reminded of the Lead Plaintiff Deadline – Contact Robbins LLP for Information on How to Lead the Class Action Against NTLA - TradingView
Faruqi & Faruqi Reminds Intellia Therapeutics Investors of - GlobeNewswire
Intellia stock plunges to 52-week low, hits $8.3 amid biotech rout - Investing.com India
NTLA LAWSUIT ALERT: The Gross Law Firm Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - TradingView
Intellia gets FDA RMAT status for Regeneron-partnered gene editing drug - Seeking Alpha
Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation - Nasdaq
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - GlobeNewswire
Intellia gains FDA fast track for gene editing therapy - Investing.com
Intellia's Gene Therapy Scores Major FDA Breakthrough: Single-Dose ATTR Heart Treatment Advances - StockTitan
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edison, Elastic, Intellia, and ICON and Encourages Investors to Contact the Firm - TradingView
2025-03-24 | Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. LawsuitNTLA | NDAQ:NTLA | Press Release - Stockhouse Publishing
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors – ... - Bluefield Daily Telegraph
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):